Research review and update: IQUIX (levofloxacin 1.5%)

International Ophthalmology Clinics

Volumn 46, Issue 4, 2006, Pages 47-60

  McDonald, Marguerite B ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; IQUIX; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BLURRED VISION; CHEMOSIS; CLINICAL TRIAL; CORNEA EROSION; CORNEA ULCER; CYTOTOXICITY; DIARRHEA; DIPLOPIA; DOSE RESPONSE; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESEARCH; DYSPEPSIA; EYE INFECTION; EYE PAIN; EYELID EDEMA; EYELID ERYTHEMA; FEVER; HEADACHE; HUMAN; HYPEREMIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TASTE DISORDER; THROAT IRRITATION; TREATMENT INDICATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DNA, BACTERIAL; EYE INFECTIONS, BACTERIAL; HUMANS; OFLOXACIN; OPHTHALMIC SOLUTIONS; TEARS; TREATMENT OUTCOME;

EID: 33750332166     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000212132.98760.72     Document Type: Review

References (13)

1. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: five-year review. Ophthalmology. 1999;106:1313-1318.
2. Chaudhry NA, Flynn HW, Murray TG, et al. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128:509-510.
3. Bui DP, Dang SB, Hwang DG. Effect of ciprofloxacin concentration on mutational resistance rates in S. aureus. Invest Ophthal Vis Sci. 1995;36.
4. Ross DL, Riley CM. Aqueous solubilities of some variously substituted quinolone antimicrobials. Int J Pharm. 1990;63:237-250.
5. Bucci FA. An in vivo comparison of the ocular absorption of levofloxacin versus ciprofloxacin prior to phacoemulsification. Am J Ophthalmol. 2004;137:308-312.
6. Levine JM, Noecker RJ, Lane LC, et al. Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing. Pharmacol Ther. 2004;20:210-216.
7. IQUIX Package insert, Santen Incorporated.
8. Clark L, Bezwada P, Hosoi K, et al. Comprehensive evaluation of topical levofloxacin in rabbit and primate models. J Toxicol Cutaneous Ocular Toxicol. 2004;23:1-18.
9. Skelnik DL, Clark LA, Bezwada P. Effect of drug concentration and exposure time of levofloxacin, ofloxacin, ciprofloxacin, gatifloxacin, and moxifloxacin on human corneal endothelial cells and keratocytes. ARVO. 2003;4739.
10. Bezwada P. Comparative ocular penetration of levofloxacin, moxifloxacin and gatifloxacin following single topical administration to the rabbit eye, Santen Incorporated, data on file.
11. Gramates PH, McDonald MB, Salib G, et al. Safety and efficacy of levofloxacin 1.5% eyedrops in nonhuman primates having penetrating keratoplasty: clinical and laboratory findings. J Cataract Refract Surg. 2005;31:1995-1998.
12. Koch HR, Kulus SC, Roessler M, et al. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. J Cataract Refract Surg. 2005;31:1377-1385.
13. Walters TR, Hart W. Tear concentration of 1.5% levofloxacin ophthalmic solution following topical administration in healthy adult volunteers. ARVO, 2003.